期刊
PROTEOMICS
卷 10, 期 4, 页码 700-716出版社
WILEY
DOI: 10.1002/pmic.200900540
关键词
Antibody; Breast cancer; Micrometastases; Multiplexing; Nanoproteomics; Quantum dot
资金
- French National Research Agency [ANR-07PNANO-051-01]
- Ligue Contre le Cancer des Ardennes, France
- NATO [SfP-983207]
- RFBRICNRS [07-04-921641PICS3868]
- RFBR [09-0400650]
- Science Foundation of Ireland
- EU FP-6 Consortium NanoInteract
- Science Foundation of Ireland SRC BioNanolnteract
The occurrence of metastases is one of the main causes of death in many cancers and the main cause of death for breast cancer patients. Micrometastases of disseminated tumour cells and circulating tumour cells are present in more than 30% of breast cancer patients without any clinical or even histopatbological signs of metastasis. Low abundance of these cell types in clinical diagnostic material dictates the necessity of their enrichment prior to reliable detection. Current micrometastases detection techniques are based on immunocytochemical and molecular methods suffering from low efficiency of tumour cells enrichment and observer-dependent interpretation. The use of highly fluorescent semiconductor nanocrystals, also known as quantum dots and nanocrystal-encoded microbeads tagged with a wide panel of antibodies against specific turnour markers offers unique possibilities for ultra-sensitive micrometastases detection in patients' serum and tissues. The nanoparticle-based diagnostics provides an opportunity for highly sensitive parallel quantification of specific proteins in a rapid and low-cost method, thereby providing a link between the primary tumour and the micrometastases for early diagnosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据